zeus slot machine
2025-01-13
Nonezeus slot machine
。
Drexel beats Pennsylvania 60-47
NEW YORK (AP) — He's making threats, traveling abroad and negotiating with world leaders. Donald Trump has more than a month and a half to go before he's sworn in for a second term. But the Republican president-elect is already moving aggressively not just to fill his Cabinet and outline policy goals, but to achieve those priorities . Trump has threatened to impose a 25% tariff on goods from Canada and Mexico, prompting emergency calls and a visit from Canada's prime minister that resulted in what Trump claimed were commitments from both U.S. allies on new border security measures. The incoming president has warned there will be “ALL HELL TO PAY" if, before his inauguration on Jan. 20, 2025, Hamas does not release the hostages being held in Gaza . He has threatened to block the purchase of U.S. Steel by a Japanese company, warning "Buyer Beware!!!” And this weekend, Trump was returning to the global stage, joining a host of other foreign leaders for the reopening of the Notre Dame Cathedral five years after it was ravaged by a fire. On Saturday, he met with French President Emmanuel Macron — joined at the last minute by Ukrainian President Volodymyr Zelenskyy — and had plans to see Britain's Prince William also in Paris. Absent in Paris: lame duck President Joe Biden, who has largely disappeared from headlines, except when he issued a pardon of his son , Hunter, who was facing sentencing for gun crimes and tax evasion. First lady Jill Biden is attending in his place. “I think you have seen more happen in the last two weeks than you’ve seen in the last four years. And we’re not even there yet,” Trump said in an over-the-top boast at an awards ceremony Thursday night . For all of Trump's bold talk, though, it is unclear how many of his efforts will bear fruit. The pre-inauguration threats and deal-making are highly unusual, like so much of what Trump does, said Julian Zelizer, a political historian at Princeton University. “Transitions are always a little complicated in this way. Even though we talk about one president at a time," he said, “the reality is one president plus. And that plus can act assertively sometimes." Zelizer said that is particularly true of Trump, who was president previously and already has relationships with many foreign leaders such as Macron, who invited both Trump and Biden to Paris this weekend as part of the Notre Dame celebration. “Right now he’s sort of governing even though he’s not the president yet. He’s having these public meetings with foreign leaders, which aren't simply introductions. He's staking out policy and negotiating things from drug trafficking to tariffs," Zelizer said. Trump already has met with several foreign leaders, in addition to a long list of calls. He hosted Argentinian President Javier Milei in Florida at his Mar-a-Lago club in November. After the tariff threat, Canadian Prime Minister Justin Trudeau made a pilgrimage to Mar-a-Lago for a three-hour dinner meeting. Canadian officials later said the country is ready to make new investments in border security, with plans for more helicopters, drones and law enforcement officers. Last Sunday, Trump dined with Sara Netanyahu, wife of the Israeli prime minister. Incoming Trump aides have also been meeting with their future foreign counterparts. On Wednesday, several members of Trump's team, including incoming national security adviser Mike Waltz, met with Andriy Yermak, a top aide to Zelenskyy, in Washington, as Ukraine tries to win support for its ongoing efforts to defend itself from Russian invasion, according to a person familiar with the meeting. Yermak also met with Trump officials in Florida, he wrote on X . That comes after Trump's incoming Middle East envoy, Steve Witkoff, traveled to Qatar and Israel for high-level talks about a cease-fire and hostage deal in Gaza, according to a U.S familiar with the efforts, meeting with the prime ministers of both countries. There is no prohibition on incoming officials or nominees meeting with foreign officials, and it is common and fine for them to do so — unless those meetings are designed to subvert or otherwise impact current U.S. policy. Trump aides were said to be especially cognizant of potential conflicts given their experience in 2016, when interactions between Trump allies and Russian officials came under scrutiny. That included a phone call in which Trump's incoming national security adviser, Michael Flynn, discussed new sanctions with Russia’s ambassador to the United States, suggesting things would improve after Trump became president. Flynn was later charged with lying to the FBI about the conversation. Trump’s incoming press secretary Karoline Leavitt said that, “All transition officials have followed applicable laws in their interactions with foreign nationals.” She added: “World leaders recognize that President Trump is returning to power and will lead with strength to put the best interests of the United States of America first again. That is why many foreign leaders and officials have reached out to correspond with President Trump and his incoming team.” Such efforts can nonetheless cause complications. If, say, Biden is having productive conversations on a thorny foreign policy issue and Trump weighs in, that could make it harder for Biden “because people are hearing two different voices” that may be in conflict, Zelizer said. Leaders like Russia's Vladimir Putin and Netanyahu may also anticipate a more favorable incoming administration and wait Biden out, hoping for more a better deal. It also remains unclear how extensively the Biden administration has been kept apprised of Trump transition efforts. Although there is no requirement that an incoming administration coordinate calls and meetings with foreign officials with the State Department or National Security Council, that has long been considered standard practice. That is, in part, because transition teams, particularly in their early days and weeks, do not always have the latest information about the state of relations with foreign nations and may not have the resources, including interpretation and logistical ability, to handle such meetings efficiently. Still, the Biden and Trump teams have been talking, particularly on the Middle East, with the incoming and outgoing administrations having agreed to work together on efforts to free hostages who remain in held in Gaza, according to a U.S. official, who, like others, was not authorized to comment publicly about the sensitive talks and spoke on condition of anonymity. That includes conversations between Witkoff and Biden’s foreign policy team as well as Waltz and Biden national security adviser Jake Sullivan. Last month, Biden administration officials said they had kept Trump’s team closely apprised of efforts to broker a ceasefire deal between Israel and Hezbollah on the Israel-Lebanon border. “I just want to be clear to all of our adversaries, they can’t play the incoming Trump administration off of the Biden administration. I’m regularly talking to the Biden people. And so, this is not a moment of opportunity or wedges for them," Waltz said Friday in a Fox Business interview. But when it comes to immigration, Biden administration officials haven’t been entirely in the loop on discussions around how to execute on Trump’s pledge to deport millions of migrants, according to four administration officials with knowledge of the transition who spoke on condition of anonymity. That’s not terribly surprising given how differently the teams view migration. Trump’s team, meanwhile, is already claiming credit for everything from gains in the stock and cryptocurrency markets to a decision by Walmart to roll back diversity, equity and inclusion policies Trump opposes. “Promises Kept — And President Trump Hasn’t Even Been Inaugurated Yet,” read one press release that claimed, in part, that both Canada and Mexico have already pledged "immediate action” to help “stem the flow of illegal immigration, human trafficking, and deadly drugs entering the United States." Mexican President Claudia Sheinbaum has stopped short of saying Trump mischaracterized their call in late November. But she said Friday that Trump “has his own way of communicating, like when we had the phone call and he wrote that we were going to close the border. That was never talked about in the phone call.” Earlier this week, Mexico carried out what it claimed was its largest seizure of fentanyl pills ever. Seizures over the summer had been as little as 50 grams per week, and after the Trump call, they seized more than a ton. Security analyst David Saucedo said that "under the pressure by Donald Trump, it appears President Claudia Sheinbaum’s administration is willing to increase the capture of drug traffickers and drug seizures that Washington is demanding.” Biden, too, tried to take credit for the seizure in a statement Friday night. ___ Associated Press writers Matthew Lee, Aamer Madhani, Colleen Long and Ellen Knickmeyer in Washington and Mark Stevenson in Mexico City contributed to this report.
DOVER, Del. (AP) — Martez Robinson's 15 points helped Delaware State defeat Loyola 80-77 on Saturday. Robinson also had seven rebounds for the Hornets (4-6). Kaseem Watson scored 14 points and added five rebounds. Alston Andrews had 13 points and shot 5 of 9 from the field and 3 of 3 from the free-throw line. Jordan Stiemke led the way for the Greyhounds (4-4) with 15 points and two steals. Loyola (MD) also got 14 points and eight rebounds from Milos Ilic. Braeden Speed also put up 13 points and four assists. Muneer Newton scored six points in the first half for Delaware State, who led 33-30 at halftime. Robinson's layup with 3:13 left in the second half gave Delaware State the lead for good at 71-70. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .None
The Latest: Police search for man who killed UnitedHealthcare CEO, new photos of suspect released
LA Galaxy strike early, hold off New York Red Bulls 2-1 to win their record 6th MLS Cup championship
The Centre for Ageing Better said data analysed on its behalf suggested more than a fifth of people in this age group are living in a poor-quality home that could be making their existing health condition worse. It said people from black and minority ethnic backgrounds, those living in London and those who have a serious health condition or disability are more likely to be affected. Data from the English Longitudinal Study of Ageing covering 2022/23 was analysed by the National Centre for Social Research on behalf of the charity. It found an estimated 4.5 million people aged 50 or older in England with a health condition aggravated by the cold are living in a home with one or more serious problems. Some 2.8 million were aged between 50 and 70, while 1.7 million were aged 70 and older. Health conditions included respiratory diseases, congestive heart failure, heart disease and lung conditions, including asthma. Housing problems identified in the research included damp, water leaks, bad condensation, electrical or plumbing problems, rot and decay. While some 2.2 million people over 50 with health and housing problems owned their home outright, the biggest proportion of people (51%) with such issues lived in rented accommodation. The charity said older renters with a health condition were up to three times more likely to have five or more issues with their home than someone in the same age group who owns their home. Those with a health condition that can be affected by poor housing who had a significant issue in their homes were most likely to live in London (52%) followed by the North East (35%) and the North West (35%), the West Midlands and the East of England (both on 28%), and the South West (27%). Almost half (46%) of people aged 50 and above from black and minority ethnic backgrounds with one of the health conditions had at least one problem with their home, which the charity said amounted to almost 500,000 people. Among white people in this age group it was just under one in three (32%). The research also suggested people from black and minority ethnic backgrounds living with a health condition were also more than twice as likely to have five or more issues with their housing compared with their white counterparts – 15% compared with 6%. Dr Carole Easton, the charity’s chief executive, said not only does the research show the difficulties faced by those living in poor housing, but it is also “very bad news” for both the economy and the NHS. She said: “Our latest research shows that our poor-quality housing crisis is putting people with health conditions in their 50s, 60s and beyond, in harm’s way. “This is obviously terrible for those individuals who live in homes that carry a very real risk of making them sick, particularly when winter comes around. “But it is also very bad news for the country. Older workers living in homes that are making their health conditions worse are going to be less likely to be able to work and help grow the economy. “Older people whose serious health conditions are made worse by their homes will require treatment, putting additional winter pressures on our health system. “All could be averted if we tackled poor-quality housing with the urgency and priority it demands.” Holly Holder, deputy director for homes at the charity, said the Government must “fix this hidden housing crisis by delivering a national strategy to tackle poor quality housing across all tenures and committing to halving the number of non-decent homes over the next decade”. She added: “No-one should have to live in a home that damages their health, yet it is the norm for far too many people in England today. “By failing to address poor-quality homes we are limiting the lives of some of the country’s poorest and most vulnerable people. “Our new analysis shows that the combination of health and house problems are most likely to impact groups of people who are already disadvantaged by multiple health and wealth inequalities.” A Government spokesperson said: “Despite the challenging inheritance faced by this Government, through our Plan for Change we’re taking action to improve housing conditions across all tenures and ensure homes are decent, safe and warm – especially for the most vulnerable. “We’re consulting on reforms to the Decent Homes Standard next year to improve the quality of social and privately rented housing, and introducing Awaab’s Law to both sectors to tackle damp, dangerous and cold conditions for all renters in England. “Our warm homes plan will also help people find ways to save money on energy bills and deliver cleaner heating, with up to 300,000 households to benefit from upgrades next year.”Georgia turns to backup Stockton to face Notre DameRochester-area mall closes early due to ‘disorderly groups’
Congenital Hyperinsulinism Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Rezolute, Hanmi Pharmaceutical, Zealand Pharma, Crinetics Pharmaceuticals 11-27-2024 07:39 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Congenital Hyperinsulinism pipeline constitutes 4+ key companies continuously working towards developing 6+ Congenital Hyperinsulinism treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Congenital Hyperinsulinism Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Congenital Hyperinsulinism Market. The Congenital Hyperinsulinism Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Congenital Hyperinsulinism Pipeline Report: https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Congenital Hyperinsulinism treatment therapies with a considerable amount of success over the years. •Congenital Hyperinsulinism companies working in the treatment market are Crinetics Pharmaceuticals, Hanmi Pharmaceutical, Rezolute, Zealand Pharma, and others, are developing therapies for the Congenital Hyperinsulinism treatment •Emerging Congenital Hyperinsulinism therapies in the different phases of clinical trials are- CRN-04777, HM 15136, RZ358, Dasiglucagon, and others are expected to have a significant impact on the Congenital Hyperinsulinism market in the coming years. •In October 2024, Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company specializing in peptide-based medicines, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon. This application is for the prevention and treatment of hypoglycemia in pediatric patients aged 7 days and older with congenital hyperinsulinism (CHI) for up to three weeks of dosing. •In September 2024, The US Food and Drug Administration (FDA) has removed the partial clinical holds on Rezolute's RZ358 (ersodetug), allowing the drug to proceed with a Phase III trial for the treatment of hypoglycemia caused by congenital hyperinsulinism (HI). This regulatory decision enables the inclusion of US participants in the ongoing global sunRIZE study. •In July 2024, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced today that it has acquired avexitide from Eiger BioPharmaceuticals, Inc. (Eiger). Avexitide has been investigated for its potential use in treating hyperinsulinemic hypoglycemia. Congenital Hyperinsulinism Overview Congenital Hyperinsulinism (CHI) is a rare genetic disorder characterized by the excessive production and secretion of insulin by the beta cells in the pancreas. Insulin is a hormone responsible for regulating blood sugar levels by promoting the uptake of glucose into cells. In individuals with congenital hyperinsulinism, there is an abnormality in the regulation of insulin secretion, leading to hypoglycemia (low blood sugar). Get a Free Sample PDF Report to know more about Congenital Hyperinsulinism Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Congenital Hyperinsulinism Drugs Under Different Phases of Clinical Development Include: •CRN-04777: Crinetics Pharmaceuticals •HM 15136: Hanmi Pharmaceutical •RZ358: Rezolute •Dasiglucagon: Zealand Pharma Congenital Hyperinsulinism Route of Administration Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Congenital Hyperinsulinism Molecule Type Congenital Hyperinsulinism Products have been categorized under various Molecule types, such as •Recombinant fusion proteins •Small molecule •Monoclonal antibody •Peptide •Polymer •Gene therapy Congenital Hyperinsulinism Pipeline Therapeutics Assessment •Congenital Hyperinsulinism Assessment by Product Type •Congenital Hyperinsulinism By Stage and Product Type •Congenital Hyperinsulinism Assessment by Route of Administration •Congenital Hyperinsulinism By Stage and Route of Administration •Congenital Hyperinsulinism Assessment by Molecule Type •Congenital Hyperinsulinism by Stage and Molecule Type DelveInsight's Congenital Hyperinsulinism Report covers around 6+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Congenital Hyperinsulinism product details are provided in the report. Download the Congenital Hyperinsulinism pipeline report to learn more about the emerging Congenital Hyperinsulinism therapies https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Congenital Hyperinsulinism Therapeutics Market include: Key companies developing therapies for Congenital Hyperinsulinism are - Zealand Pharma, Rezolute, Hanmi Pharmaceutical, Crinetics Pharmaceuticals, and others. Congenital Hyperinsulinism Pipeline Analysis: The Congenital Hyperinsulinism pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Congenital Hyperinsulinism with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Congenital Hyperinsulinism Treatment. •Congenital Hyperinsulinism key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Congenital Hyperinsulinism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Congenital Hyperinsulinism market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Congenital Hyperinsulinism drugs and therapies https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Congenital Hyperinsulinism Pipeline Market Drivers •Increase in awareness of Congenital Hyperinsulinisms, increase in research and developmental activities are some of the important factors that are fueling the Congenital Hyperinsulinism Market. Congenital Hyperinsulinism Pipeline Market Barriers •However, high-cost associated with the disease, complications associated with insulin formulation and other factors are creating obstacles in the Congenital Hyperinsulinism Market growth. Scope of Congenital Hyperinsulinism Pipeline Drug Insight •Coverage: Global •Key Congenital Hyperinsulinism Companies: Crinetics Pharmaceuticals, Hanmi Pharmaceutical, Rezolute, Zealand Pharma, and others •Key Congenital Hyperinsulinism Therapies: CRN-04777, HM 15136, RZ358, Dasiglucagon, and others •Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies •Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers Request for Sample PDF Report for Congenital Hyperinsulinism Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Congenital Hyperinsulinism Report Introduction 2. Congenital Hyperinsulinism Executive Summary 3. Congenital Hyperinsulinism Overview 4. Congenital Hyperinsulinism- Analytical Perspective In-depth Commercial Assessment 5. Congenital Hyperinsulinism Pipeline Therapeutics 6. Congenital Hyperinsulinism Late Stage Products (Phase II/III) 7. Congenital Hyperinsulinism Mid Stage Products (Phase II) 8. Congenital Hyperinsulinism Early Stage Products (Phase I) 9. Congenital Hyperinsulinism Preclinical Stage Products 10. Congenital Hyperinsulinism Therapeutics Assessment 11. Congenital Hyperinsulinism Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Congenital Hyperinsulinism Key Companies 14. Congenital Hyperinsulinism Key Products 15. Congenital Hyperinsulinism Unmet Needs 16 . Congenital Hyperinsulinism Market Drivers and Barriers 17. Congenital Hyperinsulinism Future Perspectives and Conclusion 18. Congenital Hyperinsulinism Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Congenital Hyperinsulinism Market https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Congenital Hyperinsulinism Epidemiology https://www.delveinsight.com/report-store/congenital-hyperinsulinism-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Congenital Hyperinsulinism Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports by DelveInsight •Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights •Hypogonadism Market: https://www.delveinsight.com/report-store/hypogonadism-market •Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market •Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market •Substance Use Disorder Market: https://www.delveinsight.com/report-store/substance-use-disorder-market •Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market •Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market •Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.
Lana Del Rey Credits Jack Antonoff for Her Marriage to Jeremy Dufrene: His Love For Margaret Qualley Is ‘A Big Reason’ Why She Waited to Tie the Knot
Janet Yellen tells Congress US could hit debt limit in mid-JanuaryCowboys WR CeeDee Lamb (shoulder) done for year
Men lose 17 minutes of life with every cigarette they smoke while a woman’s life is cut short by 22 minutes with each cigarette, experts have estimated. This is more than previous estimates, which suggest that each cigarette shortens a smoker’s life by 11 minutes. The new estimates, which suggest that each cigarette leads to 20 minutes loss of live on average across both genders, are based on more up-to-date figures from long-term studies tracking the health of the population. Researchers from University College London said that the harm caused by smoking is “cumulative” and the sooner a person stops smoking, and the more cigarettes they avoid smoking, the longer they live. The new analysis, commissioned by the Department for Health and Social Care, suggests that if a 10-cigarettes-a-day smoker quits on January 1, then by January 8 they could “prevent loss of a full day of life”. By February 20, their lives could be extended by a whole week. And if their quitting is successful until August 5, they will likely live for a whole month longer than if they had continued to smoke. The authors added: “Studies suggest that smokers typically lose about the same number of healthy years as they do total years of life. Make 2025 the year you quit smoking for good. There’s lots of free support available to help you. Find out more 🔽 https://t.co/J0ehnoRM1D pic.twitter.com/LQpUp6HJBm — WHH 🏥 (@WHHNHS) December 27, 2024 “Thus smoking primarily eats into the relatively healthy middle years rather than shortening the period at the end of life, which is often marked by chronic illness or disability. “So a 60-year-old smoker will typically have the health profile of a 70-year-old non-smoker.” The analysis, to be published in the Journal of Addiction, concludes: “We estimate that on average, smokers in Britain who do not quit lose approximately 20 minutes of life expectancy for each cigarette they smoke. “This is time that would likely be spent in relatively good health. “Stopping smoking at every age is beneficial but the sooner smokers get off this escalator of death the longer and healthier they can expect their lives to be.” Dr Sarah Jackson, principal research fellow from the UCL Alcohol and Tobacco Research Group, said: “It is vital that people understand just how harmful smoking is and how much quitting can improve their health and life expectancy. “The evidence suggests people lose, on average, around 20 minutes of life for each cigarette they smoke. “The sooner a person stops smoking, the longer they live. “Quitting at any age substantially improves health and the benefits start almost immediately. “It’s never too late to make a positive change for your health and there are a range of effective products and treatments that can help smokers quit for good.” There are so many reasons to quit smoking this New Year – for your health, for more money, and for your family. Make a fresh quit for 2025 – find tips and support at https://t.co/GyLk65o8kS or https://t.co/iW6WLxTL00 pic.twitter.com/KxPZ5N378y — North Tees and Hartlepool NHS Foundation Trust (@NTeesHpoolNHSFT) December 27, 2024 Health officials have said that smokers can find advice, support and resources with the NHS Quit Smoking app, as well as the online Personal Quit Plan. Public health minister Andrew Gwynne said: “Smoking is an expensive and deadly habit and these findings reveal the shocking reality of this addiction, highlighting how important it is to quit. “The new year offers a perfect chance for smokers to make a new resolution and take that step.” Commenting on the paper, Professor Sanjay Agrawal, special adviser on tobacco at the Royal College of Physicians, said: “Every cigarette smoked costs precious minutes of life, and the cumulative impact is devastating, not only for individuals but also for our healthcare system and economy. “This research is a powerful reminder of the urgent need to address cigarette smoking as the leading preventable cause of death and disease in the UK.”
2 Strong Reasons to Buy Magna Stock Like There’s No TomorrowGerry Dulac: Steelers defense failed to close out a win — again
Related hot word search:
Previous:
Next: 5 dragons slot machine